octreotide acetate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 141 Diseases   27 Trials   27 Trials   1501 News 


«1234567891011»
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    [VIRTUAL] HEPATIC ARTERY EMBOLIZATION IN A PATIENT WITH MALIGNANT INSULINOMA: A CLINICAL REPORT () -  Dec 2, 2020 - Abstract #ENEA2020ENEA_43;    
    In this clinical report, hypoglycemia started long after the diagnosis of metastatic pancreatic neuroendocrine tumor, with octreotide and diazoxide failing to control it and HAE was successful in this regard. As the large pancreatic mass persists, it is probably poorly differentiated and the control of hypoglycemia was likely obtained due to reduction of global volume of insulin secretory cells after HAE.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Trial completion date, Trial primary completion date:  Acromegaly Combination Treatment Study (clinicaltrials.gov) -  Sep 30, 2020   
    P=N/A,  N=51, Recruiting, 
    Future randomized trials should compare SSAs in the first line setting as well as the benefit of continuing them post-progression. Trial completion date: Mar 2020 --> Jun 2022 | Trial primary completion date: Mar 2020 --> Dec 2021
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Journal:  Gestational diabetes and Acromegaly: single centre experience of 14 pregnancies. (Pubmed Central) -  Sep 16, 2020   
    The prevalence of GD in our women is higher than that reported in the literature, probably resulting from the systematic GD screening and to the age of women. Therefore, routine screening of GD should be considered in women with acromegaly, particularly in those with risk factors of GD and with uncontrolled IGF-1 levels before pregnancy.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Enrollment change:  Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients (clinicaltrials.gov) -  Sep 16, 2020   
    P2,  N=5, Completed, 
    Therefore, routine screening of GD should be considered in women with acromegaly, particularly in those with risk factors of GD and with uncontrolled IGF-1 levels before pregnancy. Enrolling by invitation --> Completed | N=30 --> 5
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    [VIRTUAL] A Not so Common Finding of Dyspepsia () -  Sep 15, 2020 - Abstract #ACG2020ACG_3436;    
    Gastric NET is characterized by type 1,2 and 3 and differentiated by tumor features, gastric pH and serum gastrin level among other things. From this it allows us to determine the risk of metastasis, 5-year survival and treatment modalities that are best suited for each disease.
  • ||||||||||  Sandostatin (octreotide acetate solution for injection) / Novartis, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal:  Characterization of branched poly(lactide-co-glycolide) polymers used in injectable, long-acting formulations. (Pubmed Central) -  Sep 11, 2020   
    The Mark-Houwink plots were also used to distinguish different Glu-PLGAs. These ensemble identification methods indicate that the branch units of Glu-PLGAs extracted from Sandostatin LAR range from 2 (i.e., linear) at the lower end of the molecular weight to <4 for the majority (94%) of Glu-PLGA.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Trial completion date, Trial primary completion date, Combination therapy:  Tolvaptan-Octreotide LAR Combination in ADPKD (clinicaltrials.gov) -  Sep 7, 2020   
    P2,  N=20, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021
  • ||||||||||  Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
    Trial primary completion date, Metastases:  Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov) -  Aug 8, 2020   
    P1,  N=10, Recruiting, 
    Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021 Trial primary completion date: Jul 2020 --> Dec 2020
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Journal, Real-World Evidence:  Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors. (Pubmed Central) -  Aug 7, 2020   
    As per published guidelines, SSAs are common in first-line systemic intervention, but dose escalations and dosing deviations outside of the label are noted for symptom control. Nevertheless, oncologists must weigh the implications of the use of above-label dosing of SSAs to manage and treat patients with metastatic NET within a value-based care framework.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Journal:  Metastatic Adrenal Cortical Carcinoma Responding to Octreotide: A Case Report. (Pubmed Central) -  Aug 2, 2020   
    The next-generation sequencing-based circulating tumor DNA analysis in the patient was performed and failed to identify any alterations. These findings suggest that octreotide LAR may be a good option for the treatment of metastatic ACC in selected patients.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Sandostatin LAR Depot (octreotide acetate) / Novartis
    [VIRTUAL] I’m Not Crazy! I Get a Headache When I Pee: A Case of Metastatic Bladder Paraganglioma () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2434;    
    Because they are likely to recur and to metastasize, annual follow up with a measurement of plasma and urinary catecholamine levels and cystoscopy are essential. A functional imaging study (Ga-DOTATE scan) should be done to locate recurrence if symptoms reappear or catecholamine resurgence occurs.
  • ||||||||||  exemestane / Generic mfg., Sandostatin LAR Depot (octreotide acetate) / Novartis
    [VIRTUAL] Invasive Neuroendocrine Breast Carcinoma Presenting as Liver Metastases () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2420;    
    A functional imaging study (Ga-DOTATE scan) should be done to locate recurrence if symptoms reappear or catecholamine resurgence occurs. Patients with neuroendocrine carcinoma of the breast rarely present with clinical conditions related to hormonal hypersecretion as in neuroendocrine carcinoma of the GI tract but respond to treatment with somatostatin analogs.
  • ||||||||||  verapamil / Generic mfg., prednisone / Generic mfg., Sandostatin LAR Depot (octreotide acetate) / Novartis
    [VIRTUAL] Successful Long-Term Medical Management of Insulinomas () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2353;    
    Long-term survival data of patients with metastatic insulinoma indicates that prolonged survival is unlikely; however, most data is from the 1990s or earlier. It does not incorporate new medical treatments, or advancements in technology and the field of medicine.
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD)
    [VIRTUAL] Localization and Treatment of the Ectopic ACTH Syndrome Using Somatostatin Analogues () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2312;    
    In summary, this patient with EAS had severe clinical manifestations of hypercortisolism and could not safely undergo surgical intervention. This case demonstrates the value of SS analogues (gallium-68 dotatate PET/CT and Sandostatin LAR) in localizing and confirming the source of ectopic ACTH production and markedly improving the clinical and biochemical features of the EAS.
  • ||||||||||  olanzapine / Generic mfg., Afinitor (everolimus) / Novartis
    [VIRTUAL] A Rare Case of Metastatic Insulinoma in a Patient with Huntington’s Disease () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2300;    
    She has no history of diabetes, and only home medication is Zyprexa...Patient remains on Octreotide LAR injection every 4 weeks...Other treatment modalities include injection of octreotide, EUS-aided alcohol ablation, radio-frequency ablation or embolization of insulinoma, as well as targeted therapy with everolimus or sunitinib...Diagnosis of insulinoma is often delayed or missed as symptoms may be attributed to psychiatric, cardiac or neurological disorders or medication misuse. Clinicians should be aware of insulinoma as a cause of life-threatening hypoglycemia.
  • ||||||||||  Octreosphere (octreotide extended release) / Xbrane, Sandostatin LAR Depot (octreotide acetate) / Novartis, adecatumumab (MT201) / Amgen
    [VIRTUAL] Extended Release Octreotide Pharmacokinetics in Healthy Subjects After Subcutaneous Injection of MTD201 () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1360;    
    Reduced plasma IGF-1 concentrations were maintained throughout the study period. Unlike marketed octreotide depot products, MTD201 can be simply and rapidly reconstituted in WFI to give a stable suspension injectable via 21G needle in a 1.5mL volume.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal, HEOR:  Living With Neuroendocrine Tumors: Assessment of Quality of Life Through a Mobile Application. (Pubmed Central) -  Jun 4, 2020   
    Patients with NET experience a large symptom burden that varies daily. A decrease in physical symptoms on QoL surveys suggests an effect from daily app-based monitoring or journaling, which may reduce recall bias and benefit the patient's experience of symptoms.
  • ||||||||||  Jynarque (tolvaptan) / Otsuka, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Review, Journal:  ADPKD treatment: Tolvaptan and Octreotide (Pubmed Central) -  May 29, 2020   
    Two drugs have recently been authorized that can slow down the progression of the disease: Tolvaptan (vasopressin receptor antagonist) and Octreotide-LAR (long-acting somatostatin analogue); they both are able to reduce the activity of cyclic adenosine monophosphate (cAMP) and therefore have anti-proliferative and anti-secretory effects. This review analyzes the main trials published to date demonstrating the effects on disease progression in patients with ADPKD and illustrates the indications for identifying subjects eligible for therapy.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Journal:  Development of a novel patient-reported measure for acromegaly: the Acro-TSQ. (Pubmed Central) -  May 19, 2020   
    This is one of the largest retrospective analysis of meningioma patients treated with Sandostatin LAR (octreotide) suggesting that this treatment has minimal to no adverse events and could prolong overall survival, and progression free survival especially for patients with ER-PR+ tumors who underwent surgeries for small skull-based tumors. The Acro-TSQ is a novel PRO, focused on both disease burden and impact of treatment; it was found to be comprehensive, clear, and relevant for patients with acromegaly receiving injectable SSA treatment.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
    Enrollment change:  Comparison of Lanreotide Autogel (clinicaltrials.gov) -  Apr 30, 2020   
    P3,  N=4, Terminated, 
    Recruiting --> Active, not recruiting | N=40 --> 13 N=196 --> 4
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Trial completion date, Trial primary completion date, Metastases:  A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (clinicaltrials.gov) -  Apr 22, 2020   
    P4,  N=50, Recruiting, 
    Recruiting --> Active, not recruiting | N=176 --> 35 | Trial completion date: Apr 2021 --> Oct 2020 | Trial primary completion date: Apr 2021 --> Aug 2019 Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021
  • ||||||||||  Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
    Trial primary completion date, Metastases:  Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov) -  Apr 2, 2020   
    P1,  N=10, Recruiting, 
    Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021 Trial primary completion date: Mar 2020 --> Jul 2020
  • ||||||||||  Octreosphere (octreotide extended release) / Xbrane, Sandostatin LAR Depot (octreotide acetate) / Novartis, adecatumumab (MT201) / Amgen
    Extended Release Octreotide Pharmacokinetics in Healthy Subjects After Subcutaneous Injection of MTD201 (ENDOExpo) -  Apr 1, 2020 - Abstract #ENDO2020ENDO_4099;    
    Reduced plasma IGF-1 concentrations were maintained throughout the study period. Unlike marketed octreotide depot products, MTD201 can be simply and rapidly reconstituted in WFI to give a stable suspension injectable via 21G needle in a 1.5mL volume.